Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1976 Apr 17;1(6015):939-41.
doi: 10.1136/bmj.1.6015.939.

Impaired Lignocaine metabolism in patients with myocardial infarction and cardiac failure

Comparative Study

Impaired Lignocaine metabolism in patients with myocardial infarction and cardiac failure

L F Prescott et al. Br Med J. .

Abstract

Plasma concentrations of lignocaine were measured during and after infusion of lignocaine at 1.4 mg/min for 36-46 hours in 12 patients with myocardial infarction and one patient with cardiac failure due to uncontrolled ventricular tachycardia. In six patients without cardiac failure the plasma concentrations of lignocaine rose progressively during the infusion and the mean lignocaine half life was 4.3 hours compared with 1.4 hours in healthy subjects. Mean plasma lignocaine concentrations were significantly higher in seven patients with cardiac failure, and concentrations also rose during the infusion and the half life was considerably prolonged to 10.2 hours. Lignocaine concentrations rose rapidly to toxic levels when cardiogenic shock developed in one patient and did not fall when the infusion was stopped. The mean plasma antipyrine half life was moderately prolonged (19.4 hours) in a larger group of patients with myocardial infarction and cardiac failure but returned to normal during convalescence (13.2 hours). The metabolism of lignocaine is grossly abnormal in patients with cardiac failure and cardiogenic shock after myocardial infarction.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Br J Clin Pharmacol. 1975 Oct;2(5):429-36 - PubMed
    1. Am Heart J. 1975 Apr;89(4):470-3 - PubMed
    1. Clin Pharmacol Ther. 1975 Feb;17(2):184-94 - PubMed
    1. Clin Pharmacol Ther. 1975 Jun;17(6):669-76 - PubMed
    1. Lancet. 1973 Aug 25;2(7826):399-404 - PubMed

Publication types

LinkOut - more resources